The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Open accessAbstract
Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after <6 months (early relapse [ER]). We have recently shown an association between an immune-infiltrated tumor microenvironment (TME) and resistance to cytarabine-based chemotherapy but responsiveness to flotetuzumab, a bispecific DART antibody-based molecule to CD3ε and CD123. This paper reports the results of a multicenter, open-label, phase 1/2 study of flotetuzumab in 88 adults with relapsed/refractory AML: 42 in a dose-finding segment and 46 at the recommended phase 2 dose (RP2D) of 500 ng/kg per day. The most frequent adverse events were infusion-related reactions (IRRs)/cytokine release syndrome (CRS), largely grade 1-2. Stepwise dosing during week 1, pretreatment dexamethasone, prompt use of tocilizumab, and temporary dose reductions/interruptions successfully prevented severe IRR/CRS. Clinical benefit accrued to PIF/ER patients showing an immune-infiltrated TME. Among 30 PIF/ER patients treated at the RP2D, the complete remission (CR)/CR with partial hematological recovery (CRh) rate was 26.7%, with an overall response rate (CR/CRh/CR with incomplete hematological recovery) of 30.0%. In PIF/ER patients who achieved CR/CRh, median overall survival was 10.2 months (range, 1.87-27.27), with 6- and 12-month survival rates of 75% (95% confidence interval [CI], 0.450-1.05) and 50% (95% CI, 0.154-0.846). Bone marrow transcriptomic analysis showed that a parsimonious 10-gene signature predicted CRs to flotetuzumab (area under the receiver operating characteristic curve = 0.904 vs 0.672 for the European LeukemiaNet classifier). Flotetuzumab represents an innovative experimental approach associated with acceptable safety and encouraging evidence of activity in PIF/ER patients. This trial was registered at www.clinicaltrials.gov as #NCT02152956.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Metsalu, T., & Vilo, J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv468 · Cited by 3,709
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
Fitzgerald, J. C., Weiss, S. L., Maude, S. L., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., Shaw, P., Berg, R. A., June, C. H., Porter, D. L., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002053 · Cited by 459
Danaher, P., Warren, S., Lu, R., Samayoa, J., Sullivan, A., Pekker, I., Wallden, B., Marincola, F. M., & Cesano, A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0367-1 · Cited by 421
Sawadogo, D., Tolo, A., Kassi, H., Sangare, M., & Inwoley, A. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.023 · Cited by 381
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
Wang, S., He, Z., Wang, X., Li, H., & Liu, X.-S. (2019) · eLife · doi:10.7554/elife.49020 · Cited by 312
Testa, U., Riccioni, R., Militi, S., Coccia, E., Stellacci, E., Samoggia, P., Latagliata, R., Mariani, G., Rossini, A., Battistini, A., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0852 · Cited by 296
Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.
Muñoz, L., Nomdedeu, J. F., López, O., Carnicer, M. J., Bellido, M., Aventin, A. M., Brunet, S., & Sierra, J. (2001) · PubMed · Cited by 269
Maekawa, Y., Minato, Y., Ishifune, C., Kurihara, T., Kitamura, A., Kojima, H., Yagita, H., Sakata-Yanagimoto, M., Saito, T., Taniuchi, I., et al. (2008) · Nature Immunology · doi:10.1038/ni.1649 · Cited by 266
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Testa, U., Pelosi, E., & Frankel, A. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-4 · Cited by 255
Vadakekolathu, J., Minden, M. D., Hood, T., Church, S. E., Reeder, S., Altmann, H., Sullivan, A. H., Viboch, E. J., Patel, T., Ibrahimova, N., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz0463 · Cited by 216
Self-citationVergez, F., Green, A. S., Tamburini, J., Sarry, J.-E., Gaillard, B., Cornillet-Lefebvre, P., Pannetier, M., Neyret, A., Chapuis, N., Ifrah, N., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.047894 · Cited by 205
Johnson, S., Burke, S., Huang, L., Gorlatov, S., Li, H., Wang, W., Zhang, W., Tuaillon, N., Rainey, J., Barat, B., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.001 · Cited by 198
Self-citationTargeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform
Al-Hussaini, M., Rettig, M. P., Ritchey, J. K., Karpova, D., Uy, G. L., Eissenberg, L. G., Gao, F., Eades, W. C., Bonvini, E., Chichili, G. R., et al. (2016) · Blood · doi:10.1182/blood-2014-05-575704 · Cited by 178
Self-citationChichili, G. R., Huang, L., Li, H., Burke, S., He, L., Tang, Q., Jin, L., Gorlatov, S., Ciccarone, V., Chen, F., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5693 · Cited by 172
Self-citationTasian, S. K., Kenderian, S. S., Shen, F., Ruella, M., Shestova, O., Kozlowski, M., Li, Y., Schrank-Hacker, A., Morrissette, J. J. D., Carroll, M., et al. (2017) · Blood · doi:10.1182/blood-2016-08-736041 · Cited by 167
Estey, E. H., Kornblau, S. M., Pierce, S. A., Kantarjian, H. M., Beran, M., & Keating, M. J. (1996) · Blood · doi:10.1182/blood.v88.2.756.bloodjournal882756 · Cited by 109
Notch2 Signaling Is Required for Potent Antitumor Immunity In Vivo
Sugimoto, K., Maekawa, Y., Kitamura, A., Nishida, J., Koyanagi, A., Yagita∥, H., Kojima, H., Chiba, S., Shimada, M., & Yasutomo, K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903661 · Cited by 93
Willemze, R., Suciu, S., Archimbaud, E., Muus, P., Stryckmans, P. A., Louwagie, E. A., Berneman, Z. N., T'Jean, M., Wijermans, P., Döhner, H., et al. (1997) · PubMed · Cited by 87
Daver, N. G., Kantarjian, H. M., Ravandi, F., Estey, E. H., Wang, X., Garcia‐Manero, G., Jabbour, E. J., Konopleva, M. Y., O'Brien, S., Verstovšek, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.244 · Cited by 74
Self-citationLitzow, M. R., Othus, M. K. D., Cripe, L. D., Gore, S. D., Lazarus, H. M., Lee, S. J., Bennett, J. M., Paietta, E. M., Dewald, G. W., Rowe, J. M., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07917.x · Cited by 62
Wagner, S., Vadakekolathu, J. N., Tasian, S. K., Altmann, H., Bornhäuser, M., Pockley, A. G., Ball, G., & Rutella, S. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030726 · Cited by 55
Self-citationLi, L. J., Tao, J., Fu, R., Wang, H. Q., Jiang, H. J., Lan, Y., Zhang, W., Liu, H., & Shao, Z. H. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1590-2 · Cited by 42
Jabbour, E. J., Garcia‐Manero, G., Cortes, J. E., Ravandi, F., Plunkett, W. K., Gandhi, V. V., Faderl, S. H., O'Brien, S. M., Borthakur, G. M., Kadia, T. M., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.03.003 · Cited by 35
Self-citationSurvival outcomes of CD34+CD38−LSCs and their expression of CD123 in adult AML patients
Zahran, A. M., Aly, S. S., Rayan, A., El‐Badawy, O., Abdelfattah, M., Ali, A., ElBadre, H. M., & Hetta, . F. (2018) · Oncotarget · doi:10.18632/oncotarget.26118 · Cited by 24
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Self-citationAcute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
DiNardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00108-3 · Cited by 437
Self-citationTowards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 301
Self-citationEmerging agents and regimens for AML
Liu, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01062-w · Cited by 289
Metadata
- Authors
- Uy, G. L., Aldoss, I., Foster, M. C., Sayre, P. H., Wieduwilt, M. J., Advani, A. S., Godwin, J. E., Arellano, M. L., Sweet, K. L., Emadi, A., Ravandi, F., Erba, H. P., Byrne, M., Michaelis, L., Topp, M. S., Vey, N., Ciceri, F., Carrabba, M. G., Paolini, S., Huls, G. A., Jongen-Lavrencic, M., Wermke, M., Chevallier, P., Gyan, E., Récher, C., Stiff, P. J., Pettit, K. M., Löwenberg, B., Church, S. E., Anderson, E., Vadakekolathu, J., Santaguida, M., Rettig, M. P., Muth, J., Curtis, T., Fehr, E., Guo, K., Zhao, J., Bakkacha, O., Jacobs, K., Tran, K., Kaminker, P., Kostova, M., Bonvini, E., Walter, R. B., Davidson-Moncada, J. K., Rutella, S., & DiPersio, J. F.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-02-11
- Volume
- 137
- Issue
- 6
- Pages
- 751-762
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3085208365
- Cited by
- 326
- References
- 34
- FWCI
- 26.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.